Assessment of Oral Anticancer Medication Adherence: A Survey from a Tertiary Cancer Center

被引:1
作者
Ramachandiran, Balaji [1 ]
Dubashi, Biswajit [2 ]
Kayal, Smita [3 ]
Menon, Vikas [4 ]
Yuvaraj, K. [5 ]
Deepika, C. [5 ]
Francis, Deepa [1 ]
Debbarma, Deeksha [1 ]
Nair, Devika S. [1 ]
机构
[1] Jawaharlal Inst Post Grad Med Educ & Res, Pondicherry, India
[2] Jawaharlal Inst Post Grad Med Educ & Res, Dept Oncol, Pondicherry, India
[3] Jawaharlal Inst Post Grad Med Educ & Res, Dept Med Oncol, Pondicherry, India
[4] Jawaharlal Inst Post Grad Med Educ & Res, Dept Psychiat, Pondicherry, India
[5] Jawaharlal Inst Post Grad Med Educ & Res, Dept Prevent & Social Med, Pondicherry, India
关键词
cancer; chemotherapy; drug adherence; TAMOXIFEN; ADJUVANT; THERAPY; WOMEN;
D O I
10.1055/s-0041-1723120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Adherence to oral anticancer medication is important in cancer chemotherapy, with the advent of many oral anticancer regimens to ensure adequate cytologic response. Literature on adherence to oral anticancer therapy in India is very less. Materials and Methods This is a cross sectional analytical study consisting of all fit patients > 18 years of age taking oral anticancer therapy, with or without intravenous (IV) chemotherapy. Adherence was determined using Morisky-Green-Levine (MGL) scale, and factors affecting adherence details about cancer and treatment were obtained. All fit patients were recruited. Information was obtained using Tamil questionnaire and pro forma. Observation Of 152 patients, only 111 patients were found to be adherent to treatment. The mean age of the study population was 49.03 13.48 years. Only 12.5% of patients were aware of the diagnosis, treatment, and outcome. The study population consisted mainly of patients with chronic myeloid leukemia, colorectal carcinoma, breast carcinoma, and stomach carcinoma, which amounted for 78.3% of the study population. Bivariate analysis concluded that duration of treatment, adverse drug reaction (ADR), duration of oral anticancer drug intake in a month, coadministration with IV anticancer drugs, and frequency of drug intake (anticancer drug) were significant factors affecting drug adherence. Multivariate analysis of the above variables was insignificant, but ADR tended toward significance. Conclusion Drug adherence plays a major role in treatment outcome in cancer patients. ADR was independently associated with decreased drug adherence. Key interventions which should include counseling and behavioral modifications will reduce nonadherence.
引用
收藏
页码:127 / 130
页数:4
相关论文
共 14 条
  • [1] Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
    Demissie, S
    Silliman, RA
    Lash, TL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 322 - 328
  • [2] DiBonaventura MD, 2014, AM HEALTH DRUG BENEF, V7, P386
  • [3] Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia
    Ganesan, Prasanth
    Sagar, Tenali Gnana
    Dubashi, Biswajit
    Rajendranath, Rejiv
    Kannan, Krishnarathinam
    Cyriac, Sanju
    Nandennavar, Manjunath
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (06) : 471 - 474
  • [4] Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries
    Geissler, Jan
    Sharf, Giora
    Bombaci, Felice
    Daban, Mina
    De Jong, Jan
    Gavin, Tony
    Pelouchova, Jana
    Dziwinski, Euzebiusz
    Hasford, Joerg
    Hoffmann, Verena Sophia
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1167 - 1176
  • [5] A Systematic Review of Adherence to Oral Antineoplastic Therapies
    Greer, Joseph A.
    Amoyal, Nicole
    Nisotel, Lauren
    Fishbein, Joel N.
    MacDonald, James
    Stagl, Jamie
    Lennes, Inga
    Temel, Jennifer S.
    Safren, Steven A.
    Pirl, William F.
    [J]. ONCOLOGIST, 2016, 21 (03) : 354 - 376
  • [6] Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
    Marin, David
    Bazeos, Alexandra
    Mahon, Francois-Xavier
    Eliasson, Lina
    Milojkovic, Dragana
    Bua, Marco
    Apperley, Jane F.
    Szydlo, Richard
    Desai, Ritti
    Kozlowski, Kasia
    Paliompeis, Christos
    Latham, Victoria
    Foroni, Letizia
    Molimard, Mathieu
    Reid, Alistair
    Rezvani, Katy
    de Lavallade, Hugues
    Guallar, Cristina
    Goldman, John
    Khorashad, Jamshid S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : 2381 - 2388
  • [7] CONCURRENT AND PREDICTIVE-VALIDITY OF A SELF-REPORTED MEASURE OF MEDICATION ADHERENCE
    MORISKY, DE
    GREEN, LW
    LEVINE, DM
    [J]. MEDICAL CARE, 1986, 24 (01) : 67 - 74
  • [8] Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients
    Nilsson, J. L. G.
    Andersson, K.
    Bergkvist, A.
    Bjorkman, I.
    Brismar, A.
    Moen, J.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2006, 15 (03) : 235 - 237
  • [9] Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
    Noens, Lucien
    Hensen, Marja
    Kucmin-Bemelmans, Izabela
    Lofgren, Christina
    Gilloteau, Isabelle
    Vrijens, Bernard
    [J]. HAEMATOLOGICA, 2014, 99 (03) : 437 - 447
  • [10] Partridge AH, 2002, JNCI-J NATL CANCER I, V94, P652